callout

DACOGEN® leads to RBC transfusion independence* in all responders.12

In a randomized, controlled, phase III trial, the percentage of patients with MDS achieving transfusion independence increased with each cycle of DACOGEN treatment. 48% of patients administered DACOGEN were RBC transfusion independent by the end of cycle 3. (Figure 1) All responders became RBC transfusion independent.2

Figure 1. RBC Transfusion Independence by Cycle (All Patients)2

RBC Transfusion Independence by Cycle

Participants receiving DACOGEN demonstrated improved blood cell production:

  • Fewer participants receiving DACOGEN (20%) were treated with erythropoietic growth factors versus participants receiving supportive care (41%).2

Durable Responses

Durable Response

DACOGEN has a durable response rate associated with transfusion independence with a median duration of 41 weeks.12

Read more about Clinical Responses with DACOGEN.

References

IMPORTANT SAFETY INFORMATION

DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using DACOGEN. Men should be advised not to father a child while receiving treatment with DACOGEN, and for 2 months afterwards. The most commonly occurring adverse reactions include neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.

DACOGEN is available by prescription only. Please see the important product information for DACOGEN for more information. This site does not contain everything that is known about DACOGEN. If you would like to know more, talk to your healthcare professional.

This web site contains information relating to various medical conditions and their treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professional. You should not use this information for diagnosing a health problem or disease. Individual responses to DACOGEN treatment may vary.

This site is intended for health care professionals in the United States only. The products discussed herein may have different product labeling in different countries.

All information collected in this Web site is held in strictest confidence and will only be used for purposes as specified and will not be sold or distributed to other parties.

 
Dacogen® is a registered trademark of SuperGen, Inc., Dublin, CA, U.S.A. used under license.
Distributed and marketed by Eisai Inc.
© 2008 Eisai Inc.
All rights reserved. DAC135-B 5/08